8-K: Grace Therapeutics Announces FDA Alignment for GTx-104, Anticipates NDA Submission in Q2 2025

Grace Therapeutics has announced alignment with the FDA regarding its planned New Drug Application (NDA) submission for GTx-104, a novel injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH) patients, with the NDA submission anticipated in Q2 2025.

Summary

• Grace Therapeutics announced alignment with the FDA supporting its planned NDA submission for GTx-104.
• GTx-104 is a novel, injectable formulation of nimodipine being developed for IV infusion to address unmet medical needs in aSAH patients.
• The company anticipates filing its NDA for GTx-104 in the second quarter of 2025.
• The FDA's feedback suggests that the current data and regulatory packages are sufficient for NDA submission.
• The STRIVE-ON trial showed a 19% reduction in clinically significant hypotension with GTx-104 compared to oral nimodipine.
• 54% of patients on GTx-104 had a relative dose intensity (RDI) of 95% or higher, compared to only 8% on oral nimodipine.
• GTx-104 also showed that 29% more patients had favorable functional outcomes at 90 days.
• There were fewer ICU readmissions, ICU days, and ventilator days for patients receiving GTx-104 versus oral nimodipine.
• Adverse events were comparable between the two arms, and no new safety issues were identified with GTx-104.
• GTx-104 has been administered in over 100 patients and was well tolerated with significantly lower interand intra-subject pharmacokinetic variability compared to oral nimodipine.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the FDA alignment, promising clinical trial results, and the potential for GTx-104 to address a significant unmet medical need. However, the presence of deaths in the trial, although not attributed to the drug, tempers the overall sentiment.

Positives

• FDA alignment supports the planned NDA submission for GTx-104.
• GTx-104 demonstrated a statistically significant reduction in clinically significant hypotension compared to oral nimodipine in the STRIVE-ON trial.
• GTx-104 showed improved dose compliance compared to oral nimodipine.
• GTx-104 was associated with fewer ICU readmissions, ICU days, and ventilator days.
• GTx-104 has the potential to improve patient outcomes and deliver the first innovation for aSAH treatment in almost four decades.
• GTx-104 has been granted Orphan Drug Designation by the FDA, providing seven years of marketing exclusivity post-launch in the United States.

Negatives

• There were eight deaths on the GTx-104 arm compared to four deaths on the oral nimodipine arm, although no deaths were determined to be related to GTx-104 or oral nimodipine.
• Acceptance of the NDA will be subject to the FDA's review of the complete filing.

Risks

• The success and timing of regulatory submissions of the Phase 3 STRIVE-ON safety trial for GTx-104 is uncertain.
• Regulatory requirements or developments and the outcome and timing of the proposed NDA application for GTx-104 are subject to change.
• Legislative, regulatory, political and economic developments could impact the approval and commercialization of GTx-104.

Future Outlook

The company anticipates filing its NDA for GTx-104 in the second quarter of 2025 and believes the data and regulatory packages are sufficient for submission.

Management Comments

• Prashant Kohli, Chief Executive Officer of Grace Therapeutics, stated that the company is pleased to achieve alignment with the FDA on the substance and structure of their NDA submission.
• Prashant Kohli noted the potential of GTx-104 to improve patient outcomes upon potential FDA approval and deliver the first innovation for the treatment of aSAH in almost four decades.

Industry Context

This announcement is significant as it represents a potential advancement in the treatment of aneurysmal subarachnoid hemorrhage (aSAH), a condition with limited treatment options and high unmet medical needs. The current standard of care, oral nimodipine, has limitations, and GTx-104 offers a novel IV formulation that could address these challenges.

Comparison to Industry Standards

• Currently, oral nimodipine is the standard of care for aSAH, but it suffers from issues like variable absorption and drug interactions.
• GTx-104 aims to improve upon this by offering an IV formulation, potentially leading to more consistent drug delivery and fewer complications.
• Companies like Bausch Health, which markets nimodipine capsules, are key players in the aSAH treatment landscape, and GTx-104 could become a competitor if approved.
• The STRIVE-ON trial results suggest that GTx-104 may offer advantages over oral nimodipine in terms of hypotension, dose compliance, and functional outcomes.

Stakeholder Impact

• Shareholders may react positively to the FDA alignment and the potential for GTx-104 to become a successful product.
• Patients with aSAH could benefit from a new treatment option with improved outcomes.
• The company's employees may be motivated by the progress of GTx-104 and its potential to address a significant medical need.

Next Steps

• The company plans to submit the NDA for GTx-104 in the second quarter of 2025.
• The FDA will review the complete NDA filing.

Key Dates

Keywords

GTx-104, Grace Therapeutics, aSAH, Nimodipine, NDA, FDA, STRIVE-ON, Subarachnoid Hemorrhage, Orphan Drug Designation, Pharmaceuticals